1 Ocak 2018 Dergi makalesi Açık Erişim

Gorgulu, G.; Cicek, M. B.; Dede, B.

JSON-LD (schema.org)

{
  "@context": "https://schema.org/", 
  "@id": 32521, 
  "@type": "ScholarlyArticle", 
  "creator": [
    {
      "@type": "Person", 
      "affiliation": "Mehmet Akif Ersoy Univ, Fac Educ, Burdur, Turkey", 
      "name": "Gorgulu, G."
    }, 
    {
      "@type": "Person", 
      "affiliation": "Suleyman Demirel Univ, Fac Sci & Arts, Isparta, Turkey", 
      "name": "Cicek, M. B."
    }, 
    {
      "@type": "Person", 
      "affiliation": "Suleyman Demirel Univ, Fac Sci & Arts, Isparta, Turkey", 
      "name": "Dede, B."
    }
  ], 
  "datePublished": "2018-01-01", 
  "description": "A novel ligand, N, N ''-(4-methyl-1,2-phenylene)bis(2-(biphenyl-4-yl)-N'-hydroxy-2-oxoacetimidamide) (H2L) with its Cu(II) and Mn(II) complexes were synthesized in this study. All compounds synthesized were also characterized by H-1- and C-13-NMR, the Fourier transform infrared, elemental analysis, inductively coupled plasma optical emission spectrometry, molar conductivity, magnetic susceptibility measurements and thermogravimetric analysis. Vascular endothelial growth factor-2 (VEGFR-2) and cyclooxygenase-2 (COX-2) inhibition is often used as a parameter for being a potent anticancer agent in docking studies. For this purpose, synthesized and characterized ligand was investigated by molecular docking study to test its inhibitory effect against angiogenic factors VEGFR-2 and COX-2.", 
  "headline": "Novel Aminoketooxime Ligand and Its Cu(II) and Mn(II) Complexes: Synthesis, Characterization and Molecular Docking Studies", 
  "identifier": 32521, 
  "image": "https://aperta.ulakbim.gov.tr/static/img/logo/aperta_logo_with_icon.svg", 
  "license": "http://www.opendefinition.org/licenses/cc-by", 
  "name": "Novel Aminoketooxime Ligand and Its Cu(II) and Mn(II) Complexes: Synthesis, Characterization and Molecular Docking Studies", 
  "url": "https://aperta.ulakbim.gov.tr/record/32521"
}